immunology

Hutchmed does healthcare

Hutchmed returns to revenue growth in first half of 2026

Drugmaker Hutchmed (China) Ltd. (HCM.US; 0013.HK) on Thursday reported its revenue rose slightly in the first half of 2026, as double-digit growth for its core portfolio of cancer and immunology…
HCM.US
0013.HK

Recent Articles

RELATED ARTICLES

  1. Hutchmed does healthcare
    BRIEF: Hutchmed’s revenue drops 13% in 2025
    HCM.US
    0013.HK
  2. Niu Technologies charges into 2026 with big growth targets
  3. Texhong spins 75% profit growth in first half of 2026
    2678.HK
  4. Harbin Electric records strong profit growth in first half of 2026
    1133.HK
  5. Dtech profit rises fourfold in first half of 2026
    1377.HK
    301377.SHE
  6. CR Land’s sales rise 5% in first half of 2026 despite property downturn
    1109.HK
  7. BRIEF: iQiyi returns to revenue growth on big gains for content distribution business
    IQ.US
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva